Hello and welcome to the 2024 Annual Meeting of Stockholders of Sarepta Therapeutics Incorporated. Please note that today's meeting is being recorded. During the meeting, we'll have a question-and-answer session. You can submit questions or comments at any time by clicking on the message icon. It is now my pleasure to turn today's meeting over to Sarepta's Chairwoman of the Board of Directors, Dr. Behrens. The floor is yours. Thank you. Good morning and welcome to the 2024 Annual Meeting of Stockholders for Sarepta Therapeutics. It is now 10:00 A.M. Eastern Daylight Time, and the meeting will please come to order. My name is Dr. M. Kathleen Behrens, and as Chairwoman of the Board of Directors of Sarepta, I will be presiding over this meeting. Ryan Brown, Executive Vice President, Chief General Counsel, and Corporate Secretary will record the proceedings. I will turn to the order of business of today's meeting, which will follow the agenda that is attached in the document sections of the webcast. If you have questions or comments during the meeting, we ask that you post these questions by clicking on the messages icon in the online meeting site. Joining me today are the following current members of the Sarepta Board of Directors: Doug Ingram, Richard Barry, Dr. Kathryn Boor, Michael Chambers, Dr. Stephen Mayo, Dr. Claude Nicaise, and Dr. Hans Wigzell. I would now like to call your attention to the individuals who have agreed to stand for election as Class I Directors to the Board of Directors at this meeting: Douglas Ingram, Dr. Hans Wigzell, Dr. Kathryn Boor, and Michael Chambers. Also present today are the company's members of the Executive Committee: Douglas Ingram, President and Chief Executive Officer; Ian Estepan, Executive Vice President, Chief Financial Officer; Bilal Arif, Executive Vice President, Chief Technical Operations Officer; Diane Berry, Executive Vice President, Chief Global Policy and Advocacy Officer; Ryan Brown, Executive Vice President, Chief General Counsel, and Corporate Secretary; Dallan Murray, Executive Vice President, Chief Commercial Officer; Alison Nasisi, Executive Vice President, Chief People Officer; Louise Rodino-Klapac, Executive Vice President, Head of R&D and Chief Scientific Officer; and William Borton, Senior Vice President, Chief of Staff, Corporate Strategy, and Program Management. In addition, Stephen Briggs and Stacy Farese of KPMG, the company's independent registered public accountants, have joined us today. This morning, our program will proceed as follows. First, I will conduct the official business of the 2024 Annual Meeting. As presented in the company's Proxy Statement filed with the Securities and Exchange Commission, this year, the following are the three proposals for stakeholders to vote on: First, the election of Class I Directors. Second, the advisory vote on named executive officer compensation. Third, the ratification of KPMG LLP as the company's independent registered public accounting firm for fiscal 2024. The company has not received notice from any of its stakeholders, as required under its bylaws, of any other matters to be considered at today's meeting, and therefore, no other proposals may be properly introduced by stakeholders. We have a quorum present, which allows us to proceed to the official business of this meeting. We also have an affidavit from Computershare, the company's inspector of elections, certifying that the Notice of Internet Availability of Proxy Materials was mailed and deposited with the United States Post Office commencing on or about April 24, 2024, to each stakeholder of record as of April 8, 2024. The Board of Directors has appointed Computershare to serve as inspector of elections. Jeffrey Siders of Computershare will determine, first, the number of shares outstanding, second, the shares represented at the meeting, and third, the validity of the proxies and ballots. Mr. Siders will also tabulate the votes for this annual meeting. I will now turn to the official business of this meeting. The first matter to be voted upon is Proposal 1: The election of Class I Directors. Nominations are now in order for Class I Directors for the two-year term expiring at the 2026 Annual General Meeting of Stockholders and until their successors are duly elected and qualified. The current Board of Directors favors the election of the following individuals: Douglas S. Ingram, Dr. Hans Wigzell, Dr. Kathryn Boor, and Michael Chambers. Do we have a nomination? I hereby nominate for election as directors of the company to serve a term expiring on the date of the 2026 Annual General Meeting of Stockholders and until his or her successor is duly elected and qualified: Douglas S. Ingram, Dr. Hans Wigzell, Dr. Kathryn Boor, and Michael Chambers, who are named as director nominees in the company's proxy statement for this annual meeting. May I have a second? I second the motion. A motion to nominate the individuals listed in the proxy statement and announced at this meeting as directors of Sarepta for the two-year term expiring at the 2026 Annual General Meeting of Stockholders has been made and seconded. The second matter to be voted upon is Proposal 2: The advisory vote on the 2023 named executive compensation, excuse me, named executive officer compensation. May I have a motion? I hereby move to approve the advisory vote on 2023 named executive officer compensation. May I have a second? I second the motion. A motion to approve the advisory vote on the 2023 named executive officer compensation has been made and seconded. The third matter to be voted upon at this meeting is Proposal 3: The ratification of the selection of KPMG LLP as the independent registered public accounting firm for the company for 2024. May I have a motion? I move that the selection of KPMG as the independent registered public accounting firm for the company for 2024 be ratified and approved. May I have a second? I second the motion. A motion has been made and seconded to ratify and approve the selection of KPMG LLP as the independent registered public accounting firm for the company for the fiscal year ending December 31, 2024. We will now proceed to vote on the motions for Proposals one through three in the company's proxy statement, which are the proposals relating to the election of Class I Directors, the advisory vote on named executive officer compensation, and the ratification of the company's auditors for fiscal year 2024. Stockholders who returned a proxy card or voted via telephone or internet and do not wish to change their vote do not need to take any further action. If you wish to vote at this meeting and have not yet done so, you may do so now by clicking on the Cast Your Vote button on the web portal and following the instructions there. I am going to pause briefly now to give shareholders an opportunity to vote. I would like to thank all of our shareholders for taking the opportunity to vote in this annual proxy process for Sarepta. At this time, we will take questions from our stakeholders. When submitting your questions, please indicate your name, business affiliation, and whether you are a stakeholder or a proxy for a stakeholder. Please note only questions that are germane to the purpose of this meeting will be addressed. The company is currently in a quiet period and will not be answering questions related to the company's general business. There are no questions at this time. Thank you, Ian. Thank you for participating in this annual meeting for Sarepta. We will now close the voting polls with respect to the three proposals in the Proxy Statement. Since the voting polls are now closed, I now move that the official business portion of this meeting is concluded. May I have a second? I second the motion. Thank you very much. I would now ask Mr. Siders to summarize the tabulation of stakeholder votes on the proposals raised at this annual meeting. Thank you, Dr. Behrens. The preliminary tabulations of results are as follows: Proposal 1: Election of Directors. Our preliminary tabulation of votes received immediately prior to and at this meeting indicate that the director nominees named in the proxy statement, Douglas S. Ingram, Dr. Hans Wigzell, Dr. Kathryn Boor, and Michael Chambers, have been elected to serve for the two-year term expiring at the 2026 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified. Proposal 2: Advisory Vote on Named Executive Officer Compensation. Our preliminary tabulation of votes received immediately prior to and at this meeting indicate that the advisory vote on the 2023 named executive officer compensation has been approved. Proposal 3: Ratification of the Selection of KPMG as our independent registered public accounting firm for 2024. Our preliminary tabulation of votes received immediately prior to and at this meeting indicate that the selection of KPMG LLP as the independent registered public accounting firm for the company for the 2024 has been ratified and approved. Thank you, Mr. Siders, and thank you all for attending Sarepta's 2024 Annual Meeting of Stockholders. The meeting is now adjourned with respect to all matters. I hope you enjoy the balance of your day, and thank you again.